Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03064438 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
A Phase 2 study of Acne Rosacea, sponsored by Accuitis.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT03064438: Completed Phase 2 study of Acne Rosacea, sponsored by Accuitis.
NCT03064438 is a Phase 2 study of Acne Rosacea that has completed, run by Accuitis. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03064438, a Phase 2 study of Acne Rosacea, has completed, sponsored by Accuitis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.
Primary Outcome
Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, \<0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, \<0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG ACCU-D1
Study Locations (2)
Kentucky
- DS Research - Louisville
Texas
- DermResearch - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2018-06-18 |
| Phase | Phase 2 |
What the finished NCT03064438 record still lists
NCT03064438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Acne Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT03064438 reports a single indexed study location in Kentucky, Texas.
Frequently Asked Questions
What is clinical trial NCT03064438 about?
NCT03064438 is a clinical study titled "Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea". The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.
What is the current status of trial NCT03064438?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-11-28. Estimated completion is 2018-06-18.
What conditions does trial NCT03064438 study?
This clinical trial studies the following conditions: Acne Rosacea.
What interventions are being tested in trial NCT03064438?
The interventions under investigation include: Vehicle (DRUG), ACCU-D1 (DRUG).
Who is sponsoring clinical trial NCT03064438?
This trial is sponsored by Accuitis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03064438 being conducted?
This trial has 2 study locations across Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03064438's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI